Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

Research and Innovation Action · Running

CINDERELLA Clinical Validation of an AI-based approach to improve the shared decision-making process and outcomes in Breast Cancer Patients proposed for Locoregional treatment

Coordinator
Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud, Portugal
Runs
1 June 2022 to 30 November 2026
Status
Running
EU funding
€5.4m
Total cost
€5.4m
Partners
11 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101057389

What the project is doing

In the project's own words, from its summary on CORDIS.

Breast cancer is the most commonly diagnosed cancer, with an estimated 2.3 million new cases per year globally. Approximately 90% of these patients will undergo breast surgery with/without radiation (locoregional treatment). Different surgical techniques can be offered to the patient, each leading to completely different aesthetic outcomes. Moreover, for different patients, undergoing the same surgery, the aesthetic outcome could be completely different based on individual patient's factors (e.g, age, body habitus).

In the CINDERELLA project, we will be using the BreLO AI system (an artificial intelligence-based tool for classification of aesthetic outcomes and matching data and photographs) integrated in CANKADO (a cloud-based healthcare platform) to create an easy-to-use application that can be used on any electronic device, to simulate visually to the patient the aesthetic outcome of a certain surgery. The CINDERELLA APProach is unique as it uses a clinical database and performs biometric matching, to create images that simulate to the patient the outcome of surgery.

In the CINDERELLA trial (running during the project) we plan to compare if the application helped to fulfil the expectation and lead to a better quality of life. By feeding new clinical and photographic information to the CINDERELLA APProach after surgery, the artificial intelligence platform will be able to improve for the next cases. This trial will be practice-changing in the field of patient education and shared decision making.

CINDERELLA platform will help to overcome any miscommunication and potential boundaries in patient's or physician's understanding of the potential outcomes of locoregional treatment of breast cancer. We believe that the CINDERELLA APProach will be used in the future to other locoregional treatments that might change patients aesthetic appearance. Thus, CINDERELLA APProach will be the forerunner for new innovative tools for communicating with our patients.

Topics

Who is involved

OrganisationCityCountryRole
Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez ChampalimaudLisboaPortugalCoordinator
Kraftvoll Technologies GmbHKirchheimGermanyParticipant
Universitatsklinikum HeidelbergHeidelbergGermanyParticipant
Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical CenterRamat GanIsraelParticipant
Ospedale San Raffaele SRLMilanoItalyParticipant
Universita Commerciale Luigi BocconiMilanoItalyParticipant
Copernicus Podmiot Leczniczy Spolka Z Ograniczona OdpowiedzialnosciaGdanskPolandParticipant
Gdanski Uniwersytet MedycznyGdanskPolandParticipant
Faculdade De Ciencias Da Universidade De LisboaLisboaPortugalThird party
Fciencias.id - Associacao Para a Investigacao E Desenvolvimento De CienciasLisbonPortugalParticipant
Inesc Tec - Instituto De Engenhariade Sistemas E Computadores, Tecnologia E CienciaPortoPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI